CTX: Crescita Therapeutics Inc. - Summary | Jitta

Crescita Therapeutics Inc.

CAN:CTX

Price
CA$0.69
Loss Chance
46.1%
4.28JITTA SCORE
32.04%Over Jitta Line
Jitta Ranking
61 / 110
907 / 1,934
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (41)
Recent Business Performance (79)
Financial Strength (61)
Return to Shareholders (13)
Competitive Advantage (39)
Jitta Signs
Share RepurchaseEvery Year
Cash Conversion CycleLess than 60 days
Revenue and EarningEarning loss detected in 2021
Operating MarginInconsistent
Recent Business PerformanceEarning decline 261.14% in the last quarter (yoy)
Key Stats
Jitta Score
Jitta Line
4.28
32.04%
2.13
70.28%
2.40
107.49%
Pharmaceuticals
4.12
84.24%
4.12
84.24%
3.07
345.14%
COMPANY DESCRIPTION
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers (MMPE) and DuraPeel for the development of topicals containing cannabis and hemp. The company’s prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription portfolio offers dermocosmetic products, such as facial creams, cleansers, exfoliants, masks, serums, and suncare to treat mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea under the Laboratoire Dr Renaud brand; and provides medical aesthetics under Pro-Derm and Alyria brands, for non-invasive and minimally invasive procedures or skincare treatments. In addition, it distributes NCTF Boost 135 HA, a skin revitalization solution; Obagi Medical products; and ART FILLER, hyaluronic acid-based dermal fillers. The company has a commercialization license agreement with Cantabria Labs Inc.; and a development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.